Methods and compositions for treating ocular disorders

Details Methods and compositions for treating ocular disorders Methods and compositions for treating ocular disorders

2008-06-30

2009-12-01

Hayes, Robert C (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S912000, C514S913000

Reexamination Certificate

active

07625864

ABSTRACT:
The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.

REFERENCES:
patent: 6855690 (2005-02-01), Benowitz
patent: 7238529 (2007-07-01), Benowitz et al.
patent: 7407937 (2008-08-01), Benowitz et al.
patent: 2720069 (2008-06-01), None
patent: 97/03188 (1997-01-01), None
patent: 97/34618 (1997-07-01), None
patent: 00/13705 (2000-03-01), None
patent: 01/11086 (2001-02-01), None
Conner, J.M., et al., 2001, “Nontropic actions of neurotrophins: Subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation”, PNAS 98 (4): 1941-1946.
Pauls, T.L., et al., 1996, “The Ca2+-binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings”, Biochim. Biophys. Acta 1306: 39-54.
Kawamata, T. et al., 1997, “Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction”, PNAS 94: 8179-84.
Ritzler, J.M., et al., 1992, “The genes for the highly homologous Ca2+-binding proteins oncomodulin and parvalbumin are not linked in the human genome”, Genomics 12: 567-572.
Weidner, N., et al., 2001, “Spontaneous corticospinal axonal plasticity and functional recovery after adult central nervous system injury”, PNAS 98 (6): 3513-18.
Flanders, K.C., et al., 1998, “Transforming growth factor-betas in neurodegenerative disease”, Progress in Neurobiology 54 (1): 71-85.
Di Iorio, P. et al., 2001, “Purine nucleosides protect injured neurons and stimulate neuronal regeneration by intracellular and membrane receptor-mediated mechanisms”, Drug Development Research 52 (1-2): 303-315.
Poulsen, K.T., et al., 1994, “TGF-beta2 and TGF-beta3 are potent survival factors for midbrain dopaminergic neurons”, Neuron 13 (5): 1245-52.
English Abstract of FR 2720069, 1995.
Durkin et al., Cancer Research, vol. 43, pp. 5390-5399, 1993.
Yin et al., Nature Neuroscience, vol. 19, pp. 843-852, 2006 (Abstract Only).

Affiliated with

Also associated with

Rating

Methods and compositions for treating ocular disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treating ocular disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating ocular disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4130179